Abstract
Pulmonary embolism (PE) and deep vein thrombosis (DVT) are widely regarded as manifestations of a single disease, venous thromboembolism (VTE). An evidence-based approach to the treatment of acute VTE will be reviewed here. Currently available therapeutic options will be emphasized; possible future treatment approaches will be discussed briefly. The chronic management of VTE involves assessment of the risks and benefits of prolonged anticoagulation and is discussed in more detail elsewhere in this issue.
Keywords: Venous thromboembolism, anticoagulation, thrombolysis, Pulmonary embolism, deep vein thrombosis, vitamin K antagonists, rapid-acting gly-cosaminoglycan agent, fondaparinux, low molecular weight heparin, thrombolytic therapy, activated partial throm-boplastin time, idiopathic VTE, Systemic Thrombolysis, Pulmonary Embolectomy, Dalteparin, Enoxaparin, Tinzaparin, Inferior Vena Cava Interruption, craniotomy, caval thrombosis, DVT, tPA-induced bleeding, thrombotic syndrome, Statins, HmGCoA Reductase inhibitors, C-reactive protein, Aspirin, arterial thrombotic events, myocardial infarction, VKA-based anticoagulation, warfarin
Current Pharmaceutical Design
Title: Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism
Volume: 16 Issue: 31
Author(s): David A. Garcia
Affiliation:
Keywords: Venous thromboembolism, anticoagulation, thrombolysis, Pulmonary embolism, deep vein thrombosis, vitamin K antagonists, rapid-acting gly-cosaminoglycan agent, fondaparinux, low molecular weight heparin, thrombolytic therapy, activated partial throm-boplastin time, idiopathic VTE, Systemic Thrombolysis, Pulmonary Embolectomy, Dalteparin, Enoxaparin, Tinzaparin, Inferior Vena Cava Interruption, craniotomy, caval thrombosis, DVT, tPA-induced bleeding, thrombotic syndrome, Statins, HmGCoA Reductase inhibitors, C-reactive protein, Aspirin, arterial thrombotic events, myocardial infarction, VKA-based anticoagulation, warfarin
Abstract: Pulmonary embolism (PE) and deep vein thrombosis (DVT) are widely regarded as manifestations of a single disease, venous thromboembolism (VTE). An evidence-based approach to the treatment of acute VTE will be reviewed here. Currently available therapeutic options will be emphasized; possible future treatment approaches will be discussed briefly. The chronic management of VTE involves assessment of the risks and benefits of prolonged anticoagulation and is discussed in more detail elsewhere in this issue.
Export Options
About this article
Cite this article as:
A. Garcia David, Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563347
DOI https://dx.doi.org/10.2174/138161210793563347 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Detecting the Association Between Residual Thrombus and Post-thrombotic Classification of Chronic Venous Disease with Range Regression
Reviews on Recent Clinical Trials EDITORIAL (Thematic Issue: Novel Oral Anticoagulation-A Milestone in Anticoagulation History)
Cardiovascular & Hematological Disorders-Drug Targets Current Reviews on Renal Vein Thrombosis in Neonates
Current Pediatric Reviews Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors
Current Pharmaceutical Design Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects
Cardiovascular & Hematological Disorders-Drug Targets Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Cognitive Impairment in Systemic Lupus Erythematosus: Prevalence and Clinical Importance
Current Rheumatology Reviews Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Small Molecule Coagulation Cascade Inhibitors in the Clinic
Current Topics in Medicinal Chemistry Design and Synthesis of Novel Coumarin Conjugated Acetamides as Promising Anticancer Agents: An <i>In Silico</i> and <i>In Vitro</i> Approach
Anti-Cancer Agents in Medicinal Chemistry Novel Anti-Platelets in Stable Coronary Artery Disease
Current Pharmaceutical Design Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal
Cardiovascular & Hematological Agents in Medicinal Chemistry Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales
Current Topics in Medicinal Chemistry No-reflow: Incidence and Detection in The Cath-Lab
Current Pharmaceutical Design